Alzamend Shares Rise After FDA Gives Positive Response to Pre-IND Filing for Immune-Boosting Alzheimers Vaccine
Shares of Alzamend Neuro Inc. traded 36% higher after the company reported that the U.S. FDA responded favorably to its Pre-IND application for AL002, a cell-based therapeutic vaccine designed to restore patients immunological systems, providing them with the ability to combat Alzheimers Disease. The FDA has granted the firm approval to initiate a combined Phase 1/2 clinical trial in Q1/22.
United States Stephen Hytha Stephan Jackman Streetwise Reports Drug Administration Alzamend Neuro Inc
Source: streetwisereports.com